2/2/2023 4:55:36 PM
Gilead Sciences Q4 Non-GAAP EPS Climbs To $1.67 From $0.69 Last Year
1/30/2023 9:03:42 AM
Gilead's Kite, Arcellx Close Deal To Co-develop And Co-commercialize Late-stage Clinical CART-ddBCMA In Multiple Myeloma
1/3/2023 8:37:07 AM
Gilead Sciences, EVOQ Therapeutics Collaborate To Advance Immunotherapies
1/3/2023 8:36:34 AM
Gilead Sciences Says EMA Validates MAA For Trodelvy For Pre-treated HR+/HER2- Metastatic
Breast Cancer
12/27/2022 4:34:18 PM
Gilead To Acquire All Remaining Rights To Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
12/20/2022 8:05:27 AM
Gilead' Kite To Acquire Tmunity Therapeutics; Terms Undisclosed
12/12/2022 10:11:05 AM
Kite Announces Three-year Follow-up Data From ZUMA-5 Study For Yescarta In Relapsed Or Refractory INHL
12/11/2022 12:09:02 PM
Kite: CAR T-cell Therapy May Impact Outcomes For Patients With
R/R Large B-cell Lymphoma In CIBMTR Analysis
12/9/2022 8:31:32 AM
Kite And Arcellx To Co-develop And Co-commercialize Late-stage Clinical CART-ddBCMA In Multiple Myeloma